Artelo Biosciences Announces At-The-Market Offering Agreement

The latest update is out from Artelo Biosciences ( (ARTL) ).

On July 18, 2025, Artelo Biosciences entered into an At-The-Market Offering Agreement with R.F. Lafferty & Co., Inc. to sell up to $6,500,000 of its common stock. This agreement allows Artelo to sell shares through the Manager on the Nasdaq Capital Market or other trading platforms, providing flexibility in raising capital. The company has the option to suspend or terminate the offering, and the Manager will receive a 2% commission on sales. This move is part of Artelo’s strategy to leverage its previously filed Form S-3, which registered $75,000,000 of shares for potential offerings, enhancing its financial flexibility and market presence.

The most recent analyst rating on (ARTL) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.

Spark’s Take on ARTL Stock

According to Spark, TipRanks’ AI Analyst, ARTL is a Underperform.

Artelo Biosciences faces substantial financial hurdles with no revenue and continuous losses, heavily impacting its overall score. Technical indicators do not show a strong recovery trend, and the lack of new guidance from earnings calls further adds uncertainty. Valuation metrics are unfavorable due to negative earnings, making the stock less appealing to investors.

To see Spark’s full report on ARTL stock, click here.

More about Artelo Biosciences

Artelo Biosciences, Inc. operates in the biotechnology industry, focusing on the development of therapeutics targeting the endocannabinoid system and related pathways. The company is engaged in the research and development of proprietary compounds for treating cancer, pain, and inflammation.

Average Trading Volume: 637,438

Technical Sentiment Signal: Buy

Current Market Cap: $10.69M

See more data about ARTL stock on TipRanks’ Stock Analysis page.